PBAC to review proposal allowing GPs to start osteoporosis treatment
19 Nov 2026
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider the proposal at its March 2027 meeting. If supported, the changes would allow either a GP or a consultant physician to start treatment with romosozumab, marketed as Evenity.
Currently, GPs can only continue prescribing the medicine after a consultant physician has started the treatment. They cannot initiate it themselves.
The proposed changes would update the starting criteria, while existing rules for continuing treatment would remain the same. Telephone or online authority would still be required.
GPs could have a greater role in treatment
Professor Dimity Pond, a GP with a special interest in aged care, supports the proposed change. She said allowing GPs to start treatment would reduce unnecessary delays and make it easier for patients to access care.
She also highlighted the pressure on specialist services, noting that patients can face long waiting times and additional costs when specialist appointments are required.
Professor Pond said patients would benefit from starting treatment sooner rather than waiting for specialist approval and returning to their GP to arrange ongoing prescriptions.
How does romosozumab work?
Romosozumab is a monoclonal antibody used to treat severe osteoporosis by helping strengthen bones and increase bone density. It works by blocking a protein called sclerostin, which normally limits new bone formation.
By blocking this protein, the medicine helps increase bone mineral density and strengthen bones.
Current Australian guidelines recommend romosozumab as a first-line treatment option for post-menopausal women and men at very high risk of fractures caused by minimal trauma.
The treatment is given as two 105 mg injections under the skin once a month for 12 months.
After completing the 12-month course, patients are generally advised to move to an antiresorptive medicine, such as a bisphosphonate or denosumab, to help maintain the benefits.
Millions of Australians affected by poor bone health
An estimated 6.2 million Australians aged over 50 are living with osteoporosis or osteopenia. This figure is expected to increase by 23% to 7.7 million over the next seven years.
Projections also suggest that by 2033, an osteoporosis-related fracture could occur every 30 seconds.
With the number of people affected continuing to grow, Professor Pond is calling for GPs to give bone health greater attention, particularly among older patients.
She said bone health should receive more consideration during routine preventive health checks, alongside blood pressure, cholesterol and cardiovascular risk assessments.
Early detection and prevention remain important
Professor Pond highlighted the importance of identifying people at higher risk of osteoporosis, including those with previous fractures, thyroid conditions and women approaching or going through menopause.
She also stressed that prevention involves more than screening and medication.
Australian guidelines highlight the importance of calcium, protein, vitamin D and regular exercise in maintaining bone health and reducing fracture risk.
Professor Pond said women should be made aware that declining oestrogen levels during menopause can contribute to bone loss. She encouraged GPs to discuss healthy eating, exercise and other risk factors with patients.
She also highlighted the importance of arranging bone mineral density testing when appropriate, ensuring patients receive treatment on time and helping prevent fractures.
PBAC to review proposal allowing GPs to start osteoporosis treatment
Source: RACGP newsGP